Jennifer Kim
Stock Analyst at Cantor Fitzgerald
(1.78)
# 3,138
Out of 4,761 analysts
40
Total ratings
43.59%
Success rate
-1.06%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jennifer Kim
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Reiterates: Overweight | n/a | $81.06 | - | 8 | Feb 20, 2025 | |
| FBIO Fortress Biotech | Reiterates: Overweight | n/a | $1.62 | - | 4 | Jun 20, 2024 | |
| EYPT EyePoint Pharmaceuticals | Reiterates: Overweight | n/a | $6.15 | - | 6 | Jun 20, 2024 | |
| BLTE Belite Bio | Reiterates: Overweight | n/a | $57.00 | - | 3 | Jun 20, 2024 | |
| ALLK Allakos | Reiterates: Neutral | n/a | $0.29 | - | 4 | Jun 20, 2024 | |
| PGEN Precigen | Reiterates: Overweight | n/a | $1.91 | - | 3 | May 15, 2024 | |
| OCGN Ocugen | Maintains: Overweight | $2.5 → $2 | $0.68 | +194.12% | 2 | Aug 31, 2023 | |
| CKPT Checkpoint Therapeutics | Maintains: Overweight | $19 → $14 | $3.13 | +347.28% | 4 | Aug 15, 2023 | |
| LPCN Lipocine | Reiterates: Overweight | $33 | $3.38 | +876.33% | 2 | Jul 27, 2023 | |
| PRQR ProQR Therapeutics | Maintains: Overweight | $5 → $4.5 | $2.56 | +75.78% | 2 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $220 → $100 | $1.35 | +7,307.41% | 2 | May 17, 2022 |
Insmed
Feb 20, 2025
Reiterates: Overweight
Price Target: n/a
Current: $81.06
Upside: -
Fortress Biotech
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.62
Upside: -
EyePoint Pharmaceuticals
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $6.15
Upside: -
Belite Bio
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $57.00
Upside: -
Allakos
Jun 20, 2024
Reiterates: Neutral
Price Target: n/a
Current: $0.29
Upside: -
Precigen
May 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.91
Upside: -
Ocugen
Aug 31, 2023
Maintains: Overweight
Price Target: $2.5 → $2
Current: $0.68
Upside: +194.12%
Checkpoint Therapeutics
Aug 15, 2023
Maintains: Overweight
Price Target: $19 → $14
Current: $3.13
Upside: +347.28%
Lipocine
Jul 27, 2023
Reiterates: Overweight
Price Target: $33
Current: $3.38
Upside: +876.33%
ProQR Therapeutics
May 17, 2023
Maintains: Overweight
Price Target: $5 → $4.5
Current: $2.56
Upside: +75.78%
May 17, 2022
Maintains: Overweight
Price Target: $220 → $100
Current: $1.35
Upside: +7,307.41%